Trials Sponsors Conditions Drugs Pricing

Conditions

COVID-19

Outcome Measures

Primary Outcomes (12)

Total Protein Normal to Abnormal Transition
We examined participants who were normal at Baseline (Day 1). The Normal to Abnormal proportion reflects the proportion of participants with normal values at Day 1 that became abnormal at Day 14 relative to all participants with normal values at baseline.
14 days
Albumin Normal to Abnormal Transition
We examined participants who were normal at Baseline (Day 1). The Normal to Abnormal proportion reflects the proportion of participants with normal values at Day 1 that became abnormal at Day 14 relative to all participants with normal values at baseline.
14 days
Alkaline Phosphatase Normal to Abnormal Transition
We examined participants who were normal at Baseline (Day 1). The Normal to Abnormal proportion reflects the proportion of participants with normal values at Day 1 that became abnormal at Day 14 relative to all participants with normal values at baseline.
14 days
AST Normal to Abnormal Transition
We examined participants who were normal at Baseline (Day 1). The Normal to Abnormal proportion reflects the proportion of participants with normal values at Day 1 that became abnormal at Day 14 relative to all participants with normal values at baseline.
14 days
ALT Normal to Abnormal Transition
We examined participants who were normal at Baseline (Day 1). The Normal to Abnormal proportion reflects the proportion of participants with normal values at Day 1 that became abnormal at Day 14 relative to all participants with normal values at baseline.
14 days
Bilirubin Normal to Abnormal Transition
We examined participants who were normal at Baseline (Day 1). The Normal to Abnormal proportion reflects the proportion of participants with normal values at Day 1 that became abnormal at Day 14 relative to all participants with normal values at baseline.
14 days
Adj. EGFR Normal to Abnormal Transition
We examined participants who were normal at Baseline (Day 1). The Normal to Abnormal proportion reflects the proportion of participants with normal values at Day 1 that became abnormal at Day 14 relative to all participants with normal values at baseline.
14 days
Prothrombin Time Normal to Abnormal Transition
We examined participants who were normal at Baseline (Day 1). The Normal to Abnormal proportion reflects the proportion of participants with normal values at Day 1 that became abnormal at Day 14 relative to all participants with normal values at baseline.
14 days
APTT Normal to Abnormal Transition
We examined participants who were normal at Baseline (Day 1). The Normal to Abnormal proportion reflects the proportion of participants with normal values at Day 1 that became abnormal at Day 14 relative to all participants with normal values at baseline.
14 days
ESR Normal to Abnormal Transition
We examined participants who were normal at Baseline (Day 1). The Normal to Abnormal proportion reflects the proportion of participants with normal values at Day 1 that became abnormal at Day 14 relative to all participants with normal values at baseline.
14 days
CRP Normal to Abnormal Transition
We examined participants who were normal at Baseline (Day 1). The Normal to Abnormal proportion reflects the proportion of participants with normal values at Day 1 that became abnormal at Day 14 relative to all participants with normal values at baseline.
14 days
LDH Normal to Abnormal Transition
We examined participants who were normal at Baseline (Day 1). The Normal to Abnormal proportion reflects the proportion of participants with normal values at Day 1 that became abnormal at Day 14 relative to all participants with normal values at baseline.
14 days

Secondary Outcomes (15)

Total Bilirubin
14 days
Prothrombin Time
14 days
Aspartate Aminotransferase (AST)
14 days
Alanine Transaminase (ALT)
14 days
Albumin
14 days
+10 more secondary outcomes

Study Arms (2)

Mushrooms

EXPERIMENTAL

Fomitopsis officinalis and Trametes versicolor

Drug: FoTv

Placebo

PLACEBO COMPARATOR

Organic brown rice

Drug: FoTv

Interventions

FoTvDrug

8 capsules three times a day for 14 consecutive days.

Also known as: Fomitopsis officinalis and Trametes versicolor

MushroomsPlacebo

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersYes

Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

Positive COVID-19 diagnosis within the prior 72 hours
Age 18 years and older

Sponsors & Collaborators

Gordon Saxe
Otherlead
University of California, Irvine
Othercollaborator
University of California, Los Angeles

Study Sites (2)

University of California, Los Angeles

Los Angeles, California, 90095, United States

University of California, San Diego

San Diego, California, 92093, United States

MeSH Terms

Conditions

COVID-19

Condition Hierarchy (Ancestors)

Pneumonia, ViralPneumoniaRespiratory Tract InfectionsInfectionsVirus DiseasesCoronavirus InfectionsCoronaviridae InfectionsNidovirales InfectionsRNA Virus InfectionsLung DiseasesRespiratory Tract Diseases

Results Point of Contact

Title: Gordon Saxe, M.D./Ph.D.
Organization: Krupp Center for Integrative Research, University of California San Diego

Study Officials

Andrew Shubov, MD
University of California, Los Angeles
PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee: No
Restrictive Agreement: No

Enrollment

54 participants (actual enrollment reported by the registry).

Study Design

Study Type: interventional
Phase: phase 1 2
Allocation: RANDOMIZED
Masking: TRIPLE
Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR
Purpose: TREATMENT
Intervention Model: PARALLEL
Sponsor Type: OTHER
Responsible Party: SPONSOR INVESTIGATOR
PI Title: Director, Krupp Center for Integrative Research

Study Record Dates

First Submitted

December 3, 2020

First Posted

December 14, 2020

Study Start

December 23, 2020

Actual (reported)

RCT of Fomitopsis Officinalis and Trametes Versicolor to Treat COVID-19

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Results Posted

Conditions

Outcome Measures

Primary Outcomes (12)

Secondary Outcomes (15)

Study Arms (2)

Mushrooms

Placebo

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (2)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Results Point of Contact

Study Officials

Publication Agreements

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Documents

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Results Posted

Conditions

Outcome Measures

Primary Outcomes (12)

Secondary Outcomes (15)

Study Arms (2)

Mushrooms

Placebo

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (2)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Results Point of Contact

Study Officials

Publication Agreements

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Documents

Locations